Cooperation between p53 and the telomere-protecting shelterin component Pot1a in endometrial carcinogenesis

Oncogene

Volumn 32, Issue 17, 2013, Pages 2211-2219

  Akbay, E A ^a,b   Pena C G ^a,b   Ruder, D ^a,b   Michel, J A ^a,b   Nakada, Y ^a,b   Pathak, S ^c   Multani, A S ^c   Chang, S ^d   Castrillon, D H ^a,b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

endometrial cancer; mouse models; p53; pot1a; shelterin; telomeres

Indexed keywords

PROTEIN P53; PROTEIN POT1A; TELOMERASE; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

ANEUPLOIDY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CARCINOGENESIS; CONTROLLED STUDY; DNA DAMAGE; DOUBLE STRANDED DNA BREAK; ENDOMETRIUM CANCER; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; TELOMERE; TETRAPLOIDY;

ANEUPLOIDY; ANIMALS; CARCINOMA, ENDOMETRIOID; CELL TRANSFORMATION, NEOPLASTIC; DISEASE MODELS, ANIMAL; DNA BREAKS, DOUBLE-STRANDED; DNA-BINDING PROTEINS; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; MICE; MICE, TRANSGENIC; TELOMERE HOMEOSTASIS; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

ANIMALIA; MURINAE; MUS;

EID: 84876887956     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2012.232     Document Type: Article

References (56)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009; 59: 225-249.
2. Bokhman JV. Two pathogenetic types of endometrial carcinoma. Gynecol Oncol 1983; 15: 10-17. (Pubitemid 13194678)
3. Di Cristofano A, Ellenson LH. Endometrial carcinoma. Annu Rev Pathol 2007; 2: 57-85. (Pubitemid 46448060)
4. Clement PB, Young RH. Non-endometrioid carcinomas of the uterine corpus: a review of their pathology with emphasis on recent advances and problematic aspects. Adv Anat Pathol 2004; 11: 117-142.
5. Ueda SM, Kapp DS, Cheung MK, Shin JY, Osann K, Husain A et al. Trends in demographic and clinical characteristics in women diagnosed with corpus cancer and their potential impact on the increasing number of deaths. Am J Obstet Gynecol 2008; 198: 218e1-218e6.
6. Cirisano Jr FD, Robboy SJ, Dodge RK, Bentley RC, Krigman HR, Synan IS et al. Epidemiologic and surgicopathologic findings of papillary serous and clear cell endometrial cancers when compared to endometrioid carcinoma. Gynecol Oncol 1999; 74: 385-394. (Pubitemid 29439878)
7. Okuda T, Sekizawa A, Purwosunu Y, Nagatsuka M, Morioka M, Hayashi M et al. Genetics of endometrial cancers. Obstet Gynecol Int 2010; 2010: 984013.
8. Di Cristofano A, Pesce B, Cordon-Cardo C, Pandolfi PP. Pten is essential for embryonic development and tumour suppression. Nat Genet 1998; 19: 348-355. (Pubitemid 28357906)
9. Daikoku T, Hirota Y, Tranguch S, Joshi AR, DeMayo FJ, Lydon JP et al. Conditional loss of uterine Pten unfailingly and rapidly induces endometrial cancer in mice. Cancer Res 2008; 68: 5619-5627.
10. Kim TH, Wang J, Lee KY, Franco HL, Broaddus RR, Lydon JP et al. The synergistic effect of conditional Pten loss and oncogenic K-ras mutation on endometrial cancer development occurs via decreased progesterone receptor action. J Oncol 2010; 2010: 139087.
11. Contreras CM, Akbay EA, Gallardo TD, Haynie JM, Sharma S, Tagao O et al. Lkb1 inactivation is sufficient to drive endometrial cancers that are aggressive yet highly responsive to mTOR inhibitor monotherapy. Dis Model Mech 2010; 3: 181-193.
12. Akbay EA, Contreras CM, Perera SA, Sullivan JP, Broaddus RR, Schorge JO et al. Differential roles of telomere attrition in type I and II endometrial carcinogenesis. Am J Pathol 2008; 173: 536-544.
13. Tashiro H, Isacson C, Levine R, Kurman RJ, Cho KR, Hedrick L. p53 gene mutations are common in uterine serous carcinoma and occur early in their pathogenesis. Am J Pathol 1997; 150: 177-185. (Pubitemid 27027108)
14. Jacks T, Remington L, Williams BO, Schmitt EM, Halachmi S, Bronson RT et al. Tumor spectrum analysis in p53-mutant mice. Curr Biol 1994; 4: 1-7.
15. Batista LF, Artandi SE. Telomere uncapping, chromosomes, and carcinomas. Cancer Cell 2009; 15: 455-457.
16. Shay JW, Pereira-Smith OM, Wright WE. A role for both RB and p53 in the regulation of human cellular senescence. Exp Cell Res 1991; 196: 33-39. (Pubitemid 121006368)
17. Artandi SE, Chang S, Lee SL, Alson S, Gottlieb GJ, Chin L et al. Telomere dysfunction promotes non-reciprocal translocations and epithelial cancers in mice. Nature 2000; 406: 641-645. (Pubitemid 30641052)
18. DePinho RA, Wong KK. The age of cancer: telomeres, checkpoints, and longevity. J Clin Invest 2003; 111: S9-S14.
19. Davoli T, Denchi EL, de Lange T. Persistent telomere damage induces bypass of mitosis and tetraploidy. Cell 2010; 141: 81-93.
20. de Lange T. How telomeres solve the end-protection problem. Science 2009; 326: 948-952.
21. Palm W, de Lange T. How shelterin protects mammalian telomeres. Annu Rev Genet 2008; 42: 301-334.
22. Denchi EL, de Lange T. Protection of telomeres through independent control of ATM and ATR by TRF2 and POT1. Nature 2007; 448: 1068-1071. (Pubitemid 47345583)
23. Guo X, Deng Y, Lin Y, Cosme-Blanco W, Chan S, He H et al. Dysfunctional telomeres activate an ATM-ATR-dependent DNA damage response to suppress tumorigenesis. EMBO J. 2007; 26: 4709-4719. (Pubitemid 350126798)
24. Rai R, Li JM, Zheng H, Lok GT, Deng Y, Huen MS et al. The E3 ubiquitin ligase Rnf8 stabilizes Tpp1 to promote telomere end protection. Nat Struct Mol Biol 2011; 18: 1400-1407.
25. Thanasoula M, Escandell JM, Martinez P, Badie S, Munoz P, Blasco MA et al. p53 prevents entry into mitosis with uncapped telomeres. Curr Biol 2010; 20: 521-526.
26. de Lange T. Shelterin: the protein complex that shapes and safeguards human telomeres. Genes Dev 2005; 19: 2100-2110. (Pubitemid 41330312)
27. Hockemeyer D, Daniels JP, Takai H, de Lange T. Recent expansion of the telomeric complex in rodents: Two distinct POT1 proteins protect mouse telomeres. Cell 2006; 126: 63-77.
28. Wu L, Multani AS, He H, Cosme-Blanco W, Deng Y, Deng JM et al. Pot1 deficiency initiates DNA damage checkpoint activation and aberrant homologous recombination at telomeres. Cell 2006; 126: 49-62.
29. He H, Multani AS, Cosme-Blanco W, Tahara H, Ma J, Pathak S et al. POT1b protects telomeres from end-to-end chromosomal fusions and aberrant homologous recombination. EMBO J 2006; 25: 5180-5190. (Pubitemid 44658535)
30. Hockemeyer D, Palm W, Wang RC, Couto SS, de Lange T. Engineered telomere degradation models dyskeratosis congenita. Genes Dev 2008; 22: 1773-1785. (Pubitemid 351915502)
31. He H, Wang Y, Guo X, Ramchandani S, Ma J, Shen MF et al. Pot1b deletion and telomerase haploinsufficiency in mice initiate an ATR-dependent DNA damage response and elicit phenotypes resembling dyskeratosis congenita. Mol Cell Biol 2009; 29: 229-240.
32. Artandi SE, DePinho RA. Telomeres and telomerase in cancer. Carcinogenesis 2010; 31: 9-18.
33. Meyer LA, Broaddus RR, Lu KH. Endometrial cancer and Lynch syndrome: clinical and pathologic considerations. Cancer Control 2009; 16: 14-22.
34. Risinger JI, Berchuck A, Kohler MF, Watson P, Lynch HT, Boyd J. Genetic instability of microsatellites in endometrial carcinoma. Cancer Res 1993; 53: 5100-5103. (Pubitemid 23333372)
35. Soliman PT, Lu K. Endometrial cancer associated with defective DNA mismatch repair. Obstet Gynecol Clin North Am 2007; 34: 701-715viii.
36. Rudolph KL, Chang S, Lee HW, Blasco M, Gottlieb GJ, Greider C et al. Longevity, stress response, and cancer in aging telomerase-deficient mice. Cell 1999; 96: 701-712. (Pubitemid 29122812)
37. Friel AM, Growdon WB, McCann CK, Olawaiye AB, Munro EG, Schorge JO et al. Mouse models of uterine corpus tumors: clinical significance and utility. Front Biosci (Elite Ed) 2010; 2: 882-905.
38. Artandi SE, DePinho RA. Mice without telomerase: what can they teach us about human cancer Nat Med 2000; 6: 852-855. (Pubitemid 30644736)
39. Rudolph KL, Millard M, Bosenberg MW, DePinho RA. Telomere dysfunction and evolution of intestinal carcinoma in mice and humans. Nat Genet 2001; 28: 155-159. (Pubitemid 32538061)
40. Takai H, Smogorzewska A, de Lange T. DNA damage foci at dysfunctional telomeres. Curr Biol 2003; 13: 1549-1556. (Pubitemid 37078413)
41. d'Adda di Fagagna F, Reaper PM, Clay-Farrace L, Fiegler H, Carr P, Von Zglinicki T et al. A DNA damage checkpoint response in telomere-initiated senescence. Nature 2003; 426: 194-198. (Pubitemid 37442589)
42. Bunch JT, Bae NS, Leonardi J, Baumann P. Distinct requirements for Pot1 in limiting telomere length and maintaining chromosome stability. Mol Cell Biol 2005; 25: 5567-5578. (Pubitemid 40853591)
43. Kendellen MF, Barrientos KS, Counter CM. POT1 association with TRF2 regulates telomere length. Mol Cell Biol 2009; 29: 5611-5619.
44. Loayza D, De Lange T. POT1 as a terminal transducer of TRF1 telomere length control. Nature 2003; 423: 1013-1018. (Pubitemid 36806919)
45. MacDonald ND, Salvesen HB, Ryan A, Iversen OE, Akslen LA, Jacobs IJ. Frequency and prognostic impact of microsatellite instability in a large population-based study of endometrial carcinomas. Cancer Res 2000; 60: 1750-1752. (Pubitemid 30183451)
46. Harker WG, MacKintosh FR, Sikic BI. Development and characterization of a human sarcoma cell line, MES-SA, sensitive to multiple drugs. Cancer Res 1983; 43: 4943-4950. (Pubitemid 13015880)
47. Lax SF. Dualistic model of molecular pathogenesis in endometrial carcinoma. Zentralbl Gynakol 2002; 124: 10-16Molekulare Pathogenese des Endometriumkarzinoms auf Basis eines dualistischen Modells. (Pubitemid 34184349)
48. Noumoff JS, Simon D, Heyner S, Farber M, Haydock SW, Pritchard ML. Cytogenetics of an endometrial adenocarcinoma cell line and its implications. Gynecol Oncol 1988; 31: 217-222.
49. Deng Y, Chan SS, Chang S. Telomere dysfunction and tumour suppression: the senescence connection. Nat Rev Cancer 2008; 8: 450-458. (Pubitemid 351744962)
50. Ganem NJ, Storchova Z, Pellman D. Tetraploidy, aneuploidy and cancer. Curr Opin Genet Dev 2007; 17: 157-162. (Pubitemid 46551722)
51. Pradhan M, Abeler VM, Danielsen HE, Trope CG, Risberg BA. Image cytometry DNA ploidy correlates with histological subtypes in endometrial carcinomas. Mod Pathol 2006; 19: 1227-1235. (Pubitemid 44268193)
52. Qi L, Strong MA, Karim BO, Huso DL, Greider CW. Telomere fusion to chromosome breaks reduces oncogenic translocations and tumour formation. Nat Cell Biol 2005; 7: 706-711. (Pubitemid 40975752)
53. Forbes SA, Bindal N, Bamford S, Cole C, Kok CY, Beare D et al. COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. Nucleic Acids Res 2011; 39: D945-D950.
54. Savage SA, Giri N, Baerlocher GM, Orr N, Lansdorp PM, Alter BP. TINF2, a component of the shelterin telomere protection complex, is mutated in dyskeratosis congenita. Am J Hum Genet 2008; 82: 501-509.
55. Baerlocher GM, Lansdorp PM. Telomere length measurements using fluorescence in situ hybridization and flow cytometry. Methods Cell Biol 2004; 75: 719-750.
56. Multani AS, Ozen M, Narayan S, Kumar V, Chandra J, McConkey DJ et al. Caspasedependent apoptosis induced by telomere cleavage and TRF2 loss. Neoplasia 2000; 2: 339-345.